Feature|Articles|September 25, 2026

Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote

Listen

0:00 / 0:00

Key Takeaways

FDA movement of peptides toward 503A bulks listing advanced despite internal scientific objections citing absent human clinical evidence for most nominees and highlighting regulatory governance tensions.
Social media, GLP‑1 shortages, and affordability gaps accelerated a gray market projected at $50–$75B by 2028, pulling telehealth and consumer brands into peptide manufacturing.
Clinicians report nonspecific presentations and severe events, including CHF with MK‑677; compounded exposure may induce anti‑GLP‑1 antibodies, and products can be underdosed, impure, or adulterated.
State pharmacy boards variably police compounding with limited resources and nonmandatory adverse-event reporting; proposed guardrails include standardized API sourcing, registries with outcomes capture, and EHR visibility.

As peptides go mainstream, the FDA's shifting rules and a fractured state patchwork leave patients navigating a largely unregulated gray market.

The debate over how to regulate peptides remains unresolved, with the FDA, state pharmacy boards, and physicians offering different answers. An FDA advisory panel voted in July 2026 to recommend 6 previously restricted peptides for legal compounding,¹ despite unanimous opposition from the agency's own staff scientists, who cited an absence of human clinical data for 4 of the 7 peptides nominated.²The vote didn't resolve the regulatory debate over peptides, it exposed it.

"What's being debated right now is not whether peptides are good or bad," said Rachel Strauss, founder and CEO of PBM Princess, a pharmacy benefit consulting firm, and co-producer of the documentary "Side Effects May Include," in an interview with The American Journal of Managed Care^®(AJMC^®), "It's whether patients are being protected by these products through legitimate pharmacies and physicians, or whether they're able to buy them in this gray market that already exists."

That gray market has grown fast. Search interest in peptides has overtaken "Ozempic" on Google Trends,³ and "peptide therapy" mentions are up 281% year-over-year on Google alone.⁴Patient demand arrived years before the regulatory framework did, and the question of who is actually responsible for closing that gap is one the FDA, state pharmacy boards, and physicians are all answering differently.

FDA Peptide Category Change

In September 2023, the FDA placed BPC-157, TB-500, and 17 other peptides into "Category 2," flagging safety concerns and discouraging their compounding.¹ In February 2026, HHS Secretary Robert F. Kennedy Jr announced that roughly 14 of those 19 restricted peptides would move toward Category 1: compounding-eligible status. This is not an FDA approval, but a green light for pharmacies to work with them.^1,5 By April 2026, BPC-157 and ipamorelin were formally removed from the Category 2 list.¹Then came the July vote: the FDA's Pharmacy Compounding Advisory Committee recommended 6 peptides for the 503A Bulks List, over the unanimous objection of the agency's own scientific staff.^1,2

"The panel recognized that banning demand won't eliminate demand," Strauss said. "It's just pushing patients towards more shady places if they can't get it."

Unapproved Peptide: Fueled by GLP-1 Shortages and Social Media

The current boom traces back to the introduction of glucagon-like peptide-1s (GLP-1s). "It's been really rapid," Catherine Varney, DO, obesity medicine director at UVA Health, told AJMC, "but then once there was this acceptance of the FDA-approved peptides being widely used around 2021, the unapproved market has really exploded, because people see how beneficial the FDA-approved ones are, so they're like, ‘Well, I can't afford those.’" She said projections put the unapproved peptide market at $50 billion to $75 billion by 2028.

Strauss traced the same opening to the GLP-1 shortage era. "GLP-1s are peptides," she said. "When you had a shortage of these medications, it opened up the doors for all of these compounding pharmacies to enter the race." That relationship also blurred the public's vocabulary; she noted that patients on FDA-approved GLP-1s and patients using unrelated compounded peptides both describe themselves as simply "on peptides."

The market backs that up: Hims & Hers and Noom have both acquired manufacturing capacity to move into peptides.³ K-18, the peptide-driven hair-repair brand, which sold to Unilever for more than $1 billion in 2023, has been a template of financial and business success in the peptide industry.⁴ Additionally, podcast host Joe Rogan has credited peptides with aiding his injury recovery and has endorsed Ways2Well, an online clinic that sells them. There is a wider pattern of fitness and wellness with creators promoting compounds like BPC-157, sometimes through affiliate discount codes.³

Varney has watched the user base shift, noting, "In the last probably 5 to 6 years," she said, "the user base has really expanded from kind of the professional athlete, bodybuilders that go to the gym, to more just kind of widely based throughout the population. This is driven a lot by social media amplification, and it's being spread into the mainstream. There's this normalization of it."

Health Risks Behind Gray Market Peptides

For Varney, the clinical picture is often ahead of the conversation. "Patients know more about these than I see clinicians knowing," she said. "Patients present with really diffuse, multi-system-pattern issues, fluid retention, muscle aches, injection site reactions, and in some cases, notably with one called MK-677, some serious cardiovascular events like congestive heart failure." As the symptoms are nonspecific, she said, and patients may not disclose or even connect their peptide use to what's happening, "cases can really be missed until real harm happens to the patients."

Holly F. Lofton, MD, a clinical associate professor at NYU Grossman School of Medicine who specializes in obesity medicine, pointed to a risk specific to compounded products in an interview with AJMC: immunogenicity.

"Patients who are exposed to the compounded substances" can develop antibodies, she said, "so when they receive the FDA-approved drug later, it does not work as well, because GLP-1 antibodies do exist."

One of the biggest risks that comes with taking unregulated peptides is the sourcing. "You're getting a drug shipped to your home, and you don't know where it came from," Lofton said. "Was it someone's backyard? Was it a nice chemical lab, or was it from another country? We have to think just like street drugs; unfortunately, these drugs contain adulterants sometimes. They've been found to have things like insulin, which can be deadly, or nothing, just sugar water."

Lofton has seen the downstream result in her own practice: patients who end up in the emergency room "and we don't know what they're taking or how much they're taking or where they got it from, or we can't contact their prescriber. It's just a big question mark, and that is not safe."

FDA's Own Scientists Point to Lack of Data

The July 2026 panel vote landed despite an evidence base Varney and others describe as thin. "There was actually this scoping review in the American Journal of Sports Medicine," she said, "and they found that 67% of peptide publications were all preclinical trials, so mostly in rats, that showed some promising but variable effects." Human studies, she said, are scarce and largely uncontrolled, and broadly, "only about 5% of animal-tested interventions ever reached regulatory approval."

Angela Fitch, MD, cofounder and chief medical officer of knownwell and a past president of the Obesity Medicine Association, told AJMC, in regard to how the panel reached its recommendation anyway: "The scientists said we don't have enough data to let these be in on the bulks list," she said. "Yet another committee, most of which has serious conflicts of interest related to the fact that they sell these things in different manners in their work life, says it should be on the bulks list. That's the regulation that needs to change."

What is reaching patients isn't reliably what the label says. Varney cited systematic analyses showing gray-market peptide products contained "only 5% to 75% of what they were saying was in it,” mislabeled, in other words, alongside toxic Class 1 impurities, including arsenic, "sometimes up to 10 times the amount that you want to be injected into your body."

When asked who verifies any of this before it reaches a patient, her answer was direct: "Essentially no one that we know of." She described one of her own patients, someone with unusually high health literacy and the financial means to act on it, who told her that informal groups of users pool money to send gray-market products out for third-party purity testing themselves, because no one else is doing it.

Who Is Addressing the Regulation Gap the FDA Left Open?

At the same time, the FDA has proposed permanently closing the compounding pathway for GLP-1 drugs: semaglutide (Ozempic, Wegovy; Novo Nordisk), tirzepatide (Mounjaro, Zepbound; Eli Lilly), and liraglutide (Victoza, Saxenda; Novo Nordisk). After receiving more than 455 adverse event reports tied to compounded semaglutide alone, plus more than 320 additional reports tied to compounded tirzepatide.⁶The agency has shown it's willing to move toward shutting a pathway down when it wants to; the same hasn't been proposed for peptides, even though they rest on a thinner evidence base.

Compounding oversight mostly falls to state pharmacy boards, whose enforcement capacity varies widely and where adverse-event reporting isn't mandatory.² The result varies nationally: Connecticut, Alabama, New York, California, Massachusetts, and Louisiana have moved to restrict peptide compounding, while Texas, Florida, Nevada, and Arizona remain permissive.¹More than 40 state attorneys general have sent coordinated letters to the FDA raising safety concerns.

Fitch traces the deeper cause to how obesity treatment is covered in the first place. "The biggest gap," she said, "is just that we've never treated obesity; it's a carve-out of our standard healthcare insurance policy. It's not a standard benefit on all the insurance policies in the country that you cover obesity. It's elective." She pointed to countries that took a different approach entirely: "Several countries banned it. Australia was very early to do that; they said, ‘No, we're just not going to allow it because we can't guarantee it's safe.’"

Varney sees the same disconnect from the clinical side. Her own approach with patients who disclose peptide use is deliberately non-judgmental: a thorough history, watching for adverse effects, and an honest conversation about the lack of human safety data, even when she won't prescribe the product herself.

"Clinicians are kind of managing downstream consequences of gap regulations that haven't closed," she said. "They're not vetted, and we're just kind of catching up. Because there's not a great reporting system for this, it makes it even harder to close these gaps."

Future of Peptide Regulation

Strauss expects the next year to bring "more legitimate access" rather than either an outright ban or open season. With more physicians tracking data, more lab work required before prescribing, and, ideally, better electronic health record integration so peptide use shows up in a patient's chart.

Fitch's counterproposal is a preview of what a more rigorous version of this could have looked like from the start: enroll every compounded-product patient into something closer to a formal research framework. This includes tracked outcomes, defined standards for where the active pharmaceutical ingredient comes from, and a real adverse-event feedback loop. "That would have cost money," she said, which is a large part of why, in her view, it never happened. She also flagged a longer-term concern that hasn't been resolved either way: some peptides raise questions about angiogenesis, the growth of new blood vessels, that in theory could fuel tumor growth, a risk that simply hasn't been studied.

The open question isn't really whether peptides work. It's whether regulators, state boards, insurers, and the health care system can build guardrails fast enough to catch up with a demand that's already years ahead of them. Whether "legal" access, once it arrives, will actually solve the safety and affordability problems patients are navigating today, or just formalize them.

References